Cyterix Pharmaceuticals Inc. thinks it has found a way to safely increase the maximum tolerated dose of gemcitabine, a widely used cancer drug. The prodrugs that Cyterix is developing are meant to be activated by specific variants within a huge family of enzymes all classified as cytochrome P450 enzymes.
Also see "Cyterix Pharmaceuticals Inc." - Scrip, 1 July, 2011.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?